Literature DB >> 18397223

Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study.

Ann-Sofi Duberg1, Anna Törner, Lóa Davidsdóttir, Soo Aleman, Anders Blaxhult, Ake Svensson, Rolf Hultcrantz, Erik Bäck, Karl Ekdahl.   

Abstract

Studies on chronic viral hepatitis and mortality have often been made on selected populations or in high-endemic countries. The aim of this study was to investigate the causes of death and the mortality rates in the nationwide cohorts of people chronically infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) in Sweden, a low-endemic country. All notifications on chronic HBV infection and HCV infection 1990-2003 were linked to the Cause of Death Register. A total of 9517 people with chronic HBV infection, 34 235 people with HCV infection and 1601 with chronic HBV-HCV co-infection were included, and the mean observation times were 6.4, 6.3 and 7.9 years, respectively. The mortality in the cohorts was compared with age- and gender-specific mortality in the general population and standardized mortality ratios (SMR) were calculated. All-cause mortality was significantly increased, SMR 2.3 (HBV), 5.8 (HCV) and 8.5 (HBV-HCV), with a great excess liver-related mortality in all cohorts, SMR 21.7, 35.5 and 46.2, respectively. In HCV and HBV-HCV infected there was an increased mortality due to drug-related psychiatric diagnoses (SMR: 20.7 and 27.6) and external causes (SMR: 12.4 and 11.4), predominantly at younger age. To conclude, this study demonstrated an increased all-cause mortality, with a great excess mortality from liver disease, in all cohorts. In people with HCV infection the highest excess mortality in younger ages was from drug-related and external reasons.

Entities:  

Mesh:

Year:  2008        PMID: 18397223     DOI: 10.1111/j.1365-2893.2008.00982.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  23 in total

1.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

2.  Psychiatric care of the patient with hepatitis C: a review of the literature.

Authors:  Muhamad Aly Rifai; Ondria C Gleason; Douha Sabouni
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

3.  Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.

Authors:  Tracey G Simon; Ann-Sofi Duberg; Soo Aleman; Hannes Hagstrom; Long H Nguyen; Hamed Khalili; Raymond T Chung; Jonas F Ludvigsson
Journal:  Ann Intern Med       Date:  2019-08-20       Impact factor: 25.391

4.  Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality.

Authors:  Tracey G Simon; Ann-Sofi Duberg; Soo Aleman; Raymond T Chung; Andrew T Chan; Jonas F Ludvigsson
Journal:  N Engl J Med       Date:  2020-03-12       Impact factor: 91.245

5.  Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses.

Authors:  Jonathan P Moorman; Chun L Zhang; Lei Ni; Cheng J Ma; Ying Zhang; Xiao Y Wu; Penny Thayer; Tareq M Islam; Thomas Borthwick; Zhi Q Yao
Journal:  Vaccine       Date:  2011-03-03       Impact factor: 3.641

Review 6.  Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.

Authors:  Nathan Ford; Catherine Kirby; Kasha Singh; Edward J Mills; Graham Cooke; Adeeba Kamarulzaman; Philipp duCros
Journal:  Bull World Health Organ       Date:  2012-02-03       Impact factor: 9.408

7.  KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection.

Authors:  Lei Shi; Jia M Wang; Jun P Ren; Yong Q Cheng; Ruo S Ying; Xiao Y Wu; Shu M Lin; Jeddidiah W D Griffin; Guang Y Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Immunol       Date:  2013-12-13       Impact factor: 5.422

8.  Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection.

Authors:  Jia M Wang; Cheng J Ma; Guang Y Li; Xiao Y Wu; Penny Thayer; Pamela Greer; Ashley M Smith; Kevin P High; Jonathan P Moorman; Zhi Q Yao
Journal:  Vaccine       Date:  2013-03-14       Impact factor: 3.641

9.  Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups.

Authors:  Annunziata Faustini; Paola Colais; Emanuele Fabrizi; Anna Maria Bargagli; Marina Davoli; Domenico Di Lallo; Anteo Di Napoli; Patrizio Pezzotti; Chiara Sorge; Rita Grillo; Carla Maresca; Olga Recchia; Carlo A Perucci
Journal:  BMC Infect Dis       Date:  2010-04-19       Impact factor: 3.090

10.  Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.

Authors:  Yamini Natarajan; Donna L White; Hashem B El-Serag; David Ramsey; Peter Richardson; Jill Kuzniarek; Richa Shukla; Aylin Tansel; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2016-09-21       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.